
The CARE Foundation was established in August 2004 to:
- Build a worldwide community of physicians, veterinarians, biomedical scientists,
industrial partners, and pet owners with a common goal of advancing veterinary & human
medicine.
- Provide a mechanism to utilize animals with spontaneous disease for clinical
research.
The Foundation is classified as a Section 501(c)3 organization under the Internal Revenue
Code and is recognized as a private foundation as described in Section 509(a)1 of the Code.
Individuals, corporations, associations and foundations are eligible to support the work of
the CARE Foundation through tax-deductible gifts.
top of page
To promote and enhance the use of animals
with spontaneous disease for clinical studies through education of the health care
community and development of Registry of Spontaneous Diseases (RESPOND™)
- Promote evidence-based medicine in veterinary practice.
- Foster a global network of veterinarians, physicians, researchers & pet
owners.
- Improve understanding of spontaneous diseases of animals, their treatment and
outcomes.
- Educate researchers, clinicians, and corporate partners as to the benefits of
studying animals with spontaneous diseases.
top of page
Founding Board of Directors (Click below for Biography)
|
|
|
|
|
Theresa W. Fossum, DVM, PhD
Diplomate ACVS
President, CARE Foundation
Tom and Joan Read Chair in Veterinary Surgery
Texas A&M University,
College of Veterinary Medicine
|
|
Michael E. DeBakey, MD
Chancellor emeritus
Baylor College of Medicine,
Houston, Texas
|
|
Edwin J. Lamm III, Esq.
Lamm and Smith, P. C.,
Houston, Texas
|
Scientific Advisory Board (Click below for Biography)
top of page

- Build global awareness of spontaneous animal diseases
- Promote use of animals with spontaneous disease in clinical studies through
establishing a global registry for animals with spontaneous diseases (RESPOND™)
- Encourage evidence-based veterinary medicine
- Provide educational tools for pet owners, veterinarians, governmental agencies and
drug developers
- Decrease dependence on lab animal models for human preclinical studies
- Increase the predictive nature of critical path, preclinical drug studies; thereby
reducing time and cost of drug development for human and veterinary markets.
top of page
|
 |
 |